封面图：Beyond Half-Life: Six Routes to Longer-Acting Peptide Therapeutics Extending the half-life of a peptide is not always the same as extending its therapeutic value. The more relevant development goal is to create an exposure profile that supports the intended pharmacology, dosing interval, and the

Sichuan Pukang Pharmaceutical Phase II Facility Commissioned, Expanding Manufacturing Capacity for Long-Acting Peptide Raw Materials On May 15, 2026, the Phase II facility of Sichuan Pukang Pharmaceutical was officially completed and commissioned. Figure 1: Completion Ceremony for Phase II of Sichua

Diabodies are noncovalent dimers of single-chain antibody fragments that retain the avidity of intact IgG but have more favorable blood clearance than intact IgG. Radiometals offer a wide range of half-lives and emissions for matching imaging and therapy requirements and provide facile labeling of c

Welcome to visit us at Shanghai&Milan CPHI in 2024！

长效胰岛素：即将进入每周一次新时代 转载自 Armstrong 医药笔记 2023-09-06 08:52 发表于北京▎Armstrong 2000年，甘精胰岛素获批上市，迅速成为基础胰岛素的标准疗法，并在很长时间内成为最畅销的降糖药品种。此外，由于胰岛素的治疗窗口较窄，这让更长效的胰岛素进展缓慢。不过，近年来，诺和诺德、礼来的每周一次超长效胰岛素陆续获得突破，基础胰岛素很快将进入每周一次给药的新时代。